Michael T Bethune
Overview
Explore the profile of Michael T Bethune including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puig-Saus C, Sennino B, Peng S, Wang C, Pan Z, Yuen B, et al.
Nature
. 2023 Mar;
615(7953):697-704.
PMID: 36890230
Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells. The large HLA allele diversity and limiting clinical samples have...
2.
Foy S, Jacoby K, Bota D, Hunter T, Pan Z, Stawiski E, et al.
Nature
. 2022 Nov;
615(7953):687-696.
PMID: 36356599
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells. Here we developed a clinical-grade approach based on CRISPR-Cas9 non-viral precision genome-editing to simultaneously knockout the...
3.
Ng A, Peng S, Xu A, Noh W, Guo K, Bethune M, et al.
Lab Chip
. 2019 Sep;
19(18):3011-3021.
PMID: 31502632
Adaptive immunity is based on peptide antigen recognition. Our ability to harness the immune system for therapeutic gain relies on the discovery of the T cell receptor (TCR) genes that...
4.
Peng S, Zaretsky J, Ng A, Chour W, Bethune M, Choi J, et al.
Cell Rep
. 2019 Sep;
28(10):2728-2738.e7.
PMID: 31484081
Neoantigen-specific T cells are increasingly viewed as important immunotherapy effectors, but physically isolating these rare cell populations is challenging. Here, we describe a sensitive method for the enumeration and isolation...
5.
Li G, Bethune M, Wong S, Joglekar A, Leonard M, Wang J, et al.
Nat Methods
. 2019 Feb;
16(2):183-190.
PMID: 30700903
T cell receptor (TCR) ligand discovery is essential for understanding and manipulating immune responses to tumors. We developed a cell-based selection platform for TCR ligand discovery that exploits a membrane...
6.
Joglekar A, Leonard M, Jeppson J, Swift M, Li G, Wong S, et al.
Nat Methods
. 2019 Feb;
16(2):191-198.
PMID: 30700902
CD8 T cells recognize and eliminate tumors in an antigen-specific manner. Despite progress in characterizing the antitumor T cell repertoire and function, the identification of target antigens remains a challenge....
7.
Bethune M, Li X, Yu J, McLaughlin J, Cheng D, Mathis C, et al.
Proc Natl Acad Sci U S A
. 2018 Oct;
115(45):E10702-E10711.
PMID: 30348802
Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. Due to the prevalence of the HLA-A2 MHC class I supertype in most human...
8.
Joglekar A, Liu Z, Weber J, Ouyang Y, Jeppson J, Noh W, et al.
Proc Natl Acad Sci U S A
. 2018 Feb;
115(8):1877-1882.
PMID: 29437954
HIV controllers (HCs) are individuals who can naturally control HIV infection, partially due to potent HIV-specific CD8+ T cell responses. Here, we examined the hypothesis that superior function of CD8+...
9.
Zhou J, Bethune M, Malkova N, Sutherland A, Comin-Anduix B, Su Y, et al.
PLoS One
. 2018 Jan;
13(1):e0191634.
PMID: 29360859
For adoptive cell transfer (ACT) immunotherapy of tumor-reactive T cells, an effective therapeutic outcome depends upon cell dose, cell expansion in vivo through a minimally differentiated phenotype, long term persistence,...
10.
Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al.
Cell
. 2017 Dec;
172(3):549-563.e16.
PMID: 29275860
The immune system can mount T cell responses against tumors; however, the antigen specificities of tumor-infiltrating lymphocytes (TILs) are not well understood. We used yeast-display libraries of peptide-human leukocyte antigen...